New chemotherapy and targeted drug for a specific colon cancer type
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon or rectal adenocarcinoma that has spread (metastatic disease).
- Your tumor must show MGMT is “silenced”: MGMT gene methylation above a set threshold and no MGMT protein seen on testing.
- Your tumor must be mismatch repair–normal and microsatellite stable (often written as pMMR/MSS).
- You have not had chemotherapy specifically for metastatic disease before.
- You can provide stored tumor tissue (or fresh slides) and a blood sample for the needed biomarker tests.
- Your blood counts and organ function need to be within safe limits, and you must be able to take oral medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
This Phase 2 trial tests a chemotherapy combination (liposomal irinotecan), along with TAS-102 and bevacizumab, in people with metastatic colon cancer. It may help if your tumor has mismatch repair–proficient features and you’ve already tried standard colon cancer drugs.
This trial tests whether adding the immunotherapy drug atezolizumab (Tecentriq) to standard chemotherapy (FOLFOXIRI) and bevacizumab (Avastin) is more effective as a first treatment for people with a specific type of metastatic colorectal cancer that has a high immune score and is mismatch repair proficient.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.